EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Comparative Study on Efficacy Between Ultrasound-Guided Botulinum Toxin Type-A Injection to Salivary Glands and Oral Glycopyrrolate Therapy for Sialorrhea in Cerebral Palsy: A Randomized Controlled Trial

Indrajit De, Krishnendu Dey, Vasundhara Ghosal, Pranesh Mondal, Firdaus Kamal, Rajesh Pramanik

Journal of Pediatric Neurosciences · 09.11.2026

DOI: 10.4103/jpn.jpn_79_26 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Pediatric Neurosciences, online erschienen am 09.11.2026. Verfasst von Indrajit De und 5 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Sialorrhea is one of the most common complications in children with cerebral palsy (CP), with an incidence rate of up to 10%–58% among CP children. Glycopyrrolate has multiple anticholinergic adverse effects in the long term, while ultrasound (USG)-guided Botulinum toxin type-A (BoNT-A) injection can prove to be an effective alternative. But there is no comparative data on their efficacy. So, our purpose was to assess the comparative efficacy of the two approaches for managing sialorrhea. Materials and Methods: A single-center, open-label, randomized controlled trial was conducted over 18 months to assess improvement in sialorrhea after USG-guided BoNT-A injection to salivary glands and oral Glycopyrrolate therapy. A total of 44 CP patients were selected (22 in each group), between 4 and 12 years with Drooling severity scale (DSS) ≥3 and Drooling frequency scale (DFS) ≥3. USG-guided BoNT-A injection was given for Group-A and oral Glycopyrrolate for Group-B. Assessment was done at baseline, 2, 4, and 12 weeks post-procedure. A total of 38 patients (19 in each group) were analyzed after 6 dropouts (3 from each group).

Results

A similar reduction in both DSS and DFS was seen, from baseline (Group-A DSS 3.89 ± 0.66 and DFS 3.21 ± 0.42, Group-B DSS 3.95 ± 0.71 and DFS 3.42 ± 0.51) to 4 weeks in both groups, but at 12 weeks, statistically greater reduction ( P > 0.05) in both mean DSS and DFS for Group-A compared with Group-B. Complications were also less for Group-A compared with the others.

Conclusion

USG-guided BoNT-A injection and oral Glycopyrrolate were equally effective in controlling sialorrhea at the initial stage, till 4 weeks, whereas BoNT-A showed statistically more improvement at the later stage of the study.

Zitieren

APA

De, I., Dey, K., Ghosal, V., Mondal, P., Kamal, F., & Pramanik, R. (2026). Comparative Study on Efficacy Between Ultrasound-Guided Botulinum Toxin Type-A Injection to Salivary Glands and Oral Glycopyrrolate Therapy for Sialorrhea in Cerebral Palsy: A Randomized Controlled Trial. Journal of Pediatric Neurosciences. https://doi.org/10.4103/jpn.jpn_79_26

Vancouver

De I, Dey K, Ghosal V, Mondal P, Kamal F, Pramanik R. Comparative Study on Efficacy Between Ultrasound-Guided Botulinum Toxin Type-A Injection to Salivary Glands and Oral Glycopyrrolate Therapy for Sialorrhea in Cerebral Palsy: A Randomized Controlled Trial. Journal of Pediatric Neurosciences. 2026. doi:10.4103/jpn.jpn_79_26

BibTeX
@article{De2026,
  author = {De, Indrajit and Dey, Krishnendu and Ghosal, Vasundhara and Mondal, Pranesh and Kamal, Firdaus and Pramanik, Rajesh},
  title = {Comparative Study on Efficacy Between Ultrasound-Guided Botulinum Toxin Type-A Injection to Salivary Glands and Oral Glycopyrrolate Therapy for Sialorrhea in Cerebral Palsy: A Randomized Controlled Trial},
  journal = {Journal of Pediatric Neurosciences},
  year = {2026},
  doi = {10.4103/jpn.jpn_79_26}
}
Kostenlos starten →